Drugs / Doxorubincin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07168980 | Jul 2025 → Jun 2030 expected | B-cell non-Hodgkin lymphoma | Children's Cancer Group, China | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02405676 Background | Jan 2015 → Dec 2023 overdue | B-cell non-Hodgkin lymphoma | Children's Cancer Group, China | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Doxorubincin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07168980 ↗ |